Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
3d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Timely Access to Cancer Treatment Act of 2021 or the TACT Act of 2021 This bill requires insurance plans to authorize, and pharmacies contracted with the plans to dispense, anti-cancer oral medications within certain time frames. Specifically, within 24 hours after receiving a prescription, a pharmacy must inform the health care provider and plan enrollee whether it will dispense the medication. If the pharmacy will dispense the medication, it must do so within 72 hours after receiving the prescription. If the pharmacy is unable to dispense the medication, it must notify in writing the prescribing health care provider, the insurance plan, and the plan enrollee. A plan that requires prior authorization for anti-cancer oral medication must make that determination within 72 hours after receiving the request for authorization. Further, if a pharmacy provides notification that it is unable to dispense the medication, the health insurance plan must allow the enrollee to select a different pharmacy to dispense the medication, even if that pharmacy does not have a contract with the plan. In such a case, the plan may not require additional prior authorization or cost sharing. The Government Accountability Office must evaluate and report on the implementation of these requirements.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2022 · fourth_quarter · Pharmacy
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $810,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Client expense: $810,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · fourth_quarter · Pharmacy
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · fourth_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials HR 6584- DEPICT Act- access to clinical trials HR 6000- Cures 2.0 HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services ARPA-H FDA User Fee Agreement policy riders: increasing diversity in clinical trials, improvements to accelerated approval pathway, expanded use of real world data, and in vitro clinical tests HR 7630/S 4120- Childhood Cancer STAR Reauthorization Act of 2022- reauthorizes the STAR Act through FY2028 S 4293- Pharmacy Benefit Manager Transparency Act of 2022- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 4430- Interagency Patent Coordination and Improvement Act of 2022- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 5295/HR 9565- Comprehensive Cancer Survivorship Act- addresses the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment HR 4128/S 2209- VALID Act of 2021- requires FDA to regulate in vitro clinical tests
2022 · fourth_quarter · Medicare/Medicaid
Inflation Reduction Act (H.R. 5376) Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills) Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S. 1909) Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293) TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF. Inflation Reduction Act (HR 5376) CMMI Oncology Payment Reform
Client expense: $228,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Medicare/Medicaid
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill) Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills) Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909) Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293) CMS proposed rule to reform PBM DIR fees TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF. Inflation Reduction Act (HR 5376) CMMI Oncology Payment Reform
Client expense: $178,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Health Issues
H.R.7213 Clinical trial diversity, health equity. S.3799 Emergency preparedness and response. H.R.6000 Healthcare innovation, ARPA-H, oncology research. H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909,H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials HR 6584- DEPICT Act- access to clinical trials HR 6000- Cures 2.0 HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services ARPA-H FDA User Fee Agreement policy riders: increasing diversity in clinical trials, improvements to accelerated approval pathway, expanded use of real world data, and in vitro clinical tests HR 7630/S 4120- Childhood Cancer STAR Reauthorization Act of 2022- reauthorizes the STAR Act through FY2028 S 4293- Pharmacy Benefit Manager Transparency Act of 2022- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 4430- Interagency Patent Coordination and Improvement Act of 2022- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
Client expense: $125,406 · Firm income: Not reported
2022 · second_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials HR 6584- DEPICT Act- access to clinical trials HR 6000- Cures 2.0 HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services ARPA-H FDA User Fee Agreement Reauthorization
Client expense: $155,610 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medicare/Medicaid
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill) Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills) Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909) Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293) CMS proposed rule to reform PBM DIR fees TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF.
Client expense: $146,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications S 610/HR 1667- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials HR 6584- DEPICT Act- access to clinical trials HR 6000- Cures 2.0 ARPA-H FDA User Fee Agreement Reauthorization
Client expense: $213,980 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Medicare/Medicaid
Drug pricing aspects of the Build Back Better Act (HR 5376); House & Senate Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill) Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills) Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909) CMS proposed rule to reform PBM DIR fees TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF.
Client expense: $121,100 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
Client expense: $95,038 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity HR 5801- HELP Copays Act- copay accumulator programs S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
Client expense: $92,330 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Medicare/Medicaid
Drug pricing aspects of the Build Back Better Act (HR 5376); House & Senate Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill) Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills) Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909) TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF. Misc. provisions related to HR 3.
Client expense: $127,600 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Medicare/Medicaid
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill) Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills) TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours. Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills) Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems. Hospital and PBM consolidation. CMS/CMMI payment models, including the OCM and OCF. Misc. provisions related to HR 3.
Client expense: $78,650 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans H.R. 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals HR 4385- Cancer Drug Parity Act of 2021- oral parity
Client expense: $73,240 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Health Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans H.R. 1550 - PREVENT HPV Cancers Act of 2021 HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
Client expense: $150,047 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Pharmacy
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| OK |
| Gus M. Bilirakis | Republican | FL |
| James Comer | Republican | KY |
| John H. Rutherford | Republican | FL |
| John Joyce | Republican | PA |
| Kat Cammack | Republican | FL |
| Lee M. Zeldin | Republican | NY |
| Melanie A. Stansbury | Democratic | NM |
| Nanette Diaz Barragán | Democratic | CA |
| Ro Khanna | Democratic | CA |
| Susan Wild | Democratic | PA |
| Suzan K. DelBene | Democratic | WA |
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE